Wells Fargo lowered the firm’s price target on iTeos Therapeutics (ITOS) to $19 from $31 and keeps an Overweight rating on the shares. The firm adjusted price targets in the Smid-cap biotechnology group as part of its 2025 outlook. Wells top sector picks target Ascendis Pharma (ASND), aTyr Pharma (ATYR), Rhythm Pharmaceuticals (RYTM), and Xencor (XNCR).
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ITOS:
- iTeos Therapeutics price target lowered to $21 from $46 at H.C. Wainwright
- iTeos Therapeutics presents interim A2A-005 clinical trial data
- iTeos Therapeutics Reports Q3 2024 Financial Results
- iTeos Therapeutics reports Q3 EPS ($1.05), consensus (89c)
- Officina Stellare Secures €1.4 Million Satellite Contract